Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
CTAS$225.98-3.10(-1.35%)The Beauty Behind 'Boring' Stocks During Market Volatility5:25:48 PM ETNVDA$181.81+0.21(+0.12%)Keep Calm, Stocks Are On Sale5:25:00 PM ETGS$867.10-61.18(-6.59%)UPDATE 1-Goldman Sachs lowers gold price forecasts on hawkish Fed outlook5:22:31 PM ETMRNA$234.31-24.03(-9.30%)Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines5:20:44 PM ETAMPH$29.45+1.43(+5.10%)Amphastar Q3 revenue rises, beats expectations5:16:44 PM ETTMO$676.940.00(0.00%)Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases5:15:01 PM ETPNC$226.750.00(0.00%)PNC names Alexander Overstrom as CFO, succeeding Robert Reilly5:14:20 PM ETDOCU$78.69-1.81(-2.25%)Docusign vs. Monday.com: Which Technology Stock Is a Better Buy for 2027?5:13:02 PM ETRKLB$45.65-6.58(-12.60%)Why Rocket Lab Stock Dropped Today5:11:01 PM ETCOST$1,062.00-3.59(-0.34%)Jim Cramer Says Costco Is Still a Great Value. Charlie Munger's Rule Explains Why5:07:28 PM ETSVM$8.18-0.16(-1.92%)SILVERCORP REPORTS ADJUSTED NET INCOME OF $18.4 MILLION, $0.08 PER SHARE, AND CASH FLOW FROM OPERATING ACTIVITIES OF $62.7 MILLION FOR Q2 FISCAL 20275:06:04 PM ETABNB$187.49+11.12(+6.30%)Airbnb Shares Climb on Q3 Earnings Double-Beat: Details5:05:49 PM ETNET$283.70+39.19(+16.03%)Cloudflare Q3 revenue beats estimates on AI platform demand5:05:25 PM ETINTC$51.82-6.46(-11.08%)Stock Market Today, Nov. 5: Intel Falls on Weak Fourth-Quarter Sales Outlook Amid Chip Selloff5:02:16 PM ETTMO$676.940.00(0.00%)Thermo Fisher Scientific Announces Quarterly Dividend5:00:04 PM ETWPM$129.11-3.35(-2.53%)Wheaton Precious Metals Announces Third Quarter 2026 Results and Record Year-to-Date Production, Sales Volume, Revenue, Earnings and Cash Flow5:00:00 PM ETTSX:SAP$41.620.00(0.00%)Saputo Reports Financial Results for the Second Quarter of Fiscal 2027 Ended September 30, 20265:00:00 PM ETNET$283.70+39.19(+16.03%)Cloudflare Stock Surges on Lifted Full-Year Outlook, Third-Quarter Revenue Growth5:00:00 PM ETMNST$44.64-3.19(-6.67%)Monster Beverage Q3 sales beat estimates as marketing investments boost results4:56:44 PM ETEOG$144.890.00(0.00%)UPDATE 2-US shale producer EOG Resources beats profit estimates on higher crude prices4:55:18 PM ETCVX$213.59+0.66(+0.31%)Chevron (CVX) Price Forecast: Critical Support Faces First Major Test4:54:45 PM ETAAPL$342.53-7.03(-2.01%)Market Close: Stocks Tumble, Apple To Sell $7B In Debt, Wendy's Rejects Buyout Bid 11-5-20264:52:29 PM ETANTUPDATE 1-A&O Shearman's $1.1 billion AI plan builds on law firms' tech investments4:51:58 PM ETDNA$9.51-0.45(-4.52%)Ginkgo Bioworks Q3 revenue falls compared to last year4:51:51 PM ET

RZLT · NASDAQ

Rezolute, Inc.

$3.64 -0.32 (-7.96%)

Company overview

Rezolute, Inc. is a clinical-stage biopharmaceutical company that develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$352M
Employees
64
Headquarters
Redwood City, CA
Website
rezolutebio.com
CEO
Nevan Charles Elam
Listed
January 14, 2013
P/E
-4.44
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$23,000
Operating income
-$87.3M
EBITDA
-$85.6M
Net income
-$81.5M
EPS
-$0.82
Total assets
$125M
Total debt
$1.1M
Earnings yield
-22.53%

Price chart

2.723.484.234.995.75
RZLT 1D NASDAQ O4.12H4.34L3.95C3.96-0.05 (-1.25%)Vol1.07M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
RZLTRezolute, Inc. Stock news Rezolute Q1 loss widens slightly; sees Phase 3 tumor HI data by mid-Dec 2026 Reuters
RZLTRezolute, Inc. Stock news BRIEF-Rezolute Q1 EPS USD -0.18 Reuters
RZLTRezolute, Inc. Press release Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update GlobeNewswire
RZLTRezolute, Inc. Press release Rezolute to Participate in Upcoming Investor Conferences GlobeNewswire
RZLTRezolute, Inc. Press release Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism GlobeNewswire
RZLTRezolute, Inc. Stock news Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts Defense World
RZLTRezolute, Inc. Press release Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism GlobeNewswire
RZLTRezolute, Inc. Stock news This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Benzinga
RZLTRezolute, Inc. Press release Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update GlobeNewswire
RZLTRezolute, Inc. Stock news Rezolute, Inc. (NASDAQ:RZLT) Receives $9.38 Average Price Target from Analysts Defense World
RZLTRezolute, Inc. Press release Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism GlobeNewswire
RZLTRezolute, Inc. Press release Rezolute to Participate in Upcoming Investor Conferences GlobeNewswire
RZLTRezolute, Inc. Stock news Rezolute, Inc. $RZLT Shares Sold by Bank of America Corp DE Defense World
RZLTRezolute, Inc. Press release Rezolute to Participate in the BTIG Virtual Biotechnology Conference GlobeNewswire
RZLTRezolute, Inc. Stock news RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? Zacks Investment Research
RZLTRezolute, Inc. Press release Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society GlobeNewswire
RZLTRezolute, Inc. Stock news Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study Benzinga
RZLTRezolute, Inc. Press release Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism GlobeNewswire
RZLTRezolute, Inc. Press release Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update GlobeNewswire
RZLTRezolute, Inc. Press release Rezolute to Participate in Upcoming Investor Conferences GlobeNewswire
See more
FAQ

Questions about Rezolute, Inc.

What does Rezolute, Inc. do?
Rezolute, Inc. is a clinical-stage biopharmaceutical company that develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
What is RZLT's market cap?
Rezolute, Inc. (RZLT) is a listed stock with a live quote. The latest market cap on this page is $352M.
Where is Rezolute, Inc. headquartered?
Rezolute, Inc. is headquartered in Redwood City, CA.
How do I get RZLT news from the API?
Call GET /v1/news?tickers=RZLT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does RZLT news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for RZLT, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the RZLT price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs